We have been waiting for an attractive entry point to buy Fabrinet (NYSE:FN) for a couple of months now as the stock has continued its impressive climb upwards. And, after the stock’s recent sell-off over the past few weeks, we believe that now is a great time to buy.
Click to enlarge
Brief Company Overview
Fabrinet is a high-tech contract manufacturer for some of the world’s largest OEM’s that serve the optical communication, laser, medical, industrial, and automotive end markets. Here is a more specific explanation of what they do & make, from two sections of their most recent investor presentation:
Top 5 Medical Stocks To Invest In 2018: Realogy Holdings Corp.(RLGY)
- [By Monica Wolfe]
Realogy Holdings (RLGY)
Paulsons third largest holding goes to Realogy Holdings. The guru holds on to 12,957,700 shares, representing 4.4% of his total portfolio and 8.87% of the companys shares outstanding.
- [By Lisa Abramowicz]
Drugstore chain Rite Aid Corp. (RAD) and residential property firm Realogy Corp. (RLGY) are two of the 283 junk-rated borrowers identified in March 2009 by Moodys Investors Service as being at the highest risk of default that have since sold bonds.
- [By Chad Tracy]
Investments in Claire's retail stores, Realogy Holdings (NYSE: RLGY), and Harrah's Entertainment all came under pressure as the global credit crisis hit. Apollo was forced to shut off cash interest payments to investors and to issue more debt.
Top 5 Medical Stocks To Invest In 2018: Vitality Biopharma (VBIO)
- [By Jim Robertson]
Yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announcedthe filing of an international patent application that describes compounds discovered to be effective for neural repair treatments. The underlying patent rights were assigned to Vitality Biopharma in March 2016 and are based on work performed by the Myelin Repair Foundation (MRF) -a non-profit disease research organization that was dedicated to developing regenerative therapies for multiple sclerosis.
- [By James E. Brumley]
Investors who were looking to learn a little more about up-and-coming drug development company Vitality Biopharma Inc (OTCMKTS:VBIO) may want to mark December 8th on their calendar…. if they’re going to be in the Los Angeles area that day anyway. The company will be making a presentation that day, at the annual LD Micro Main Event. Interested and approved investors can attend the VBIO presentation by registering beforehand with LD Micro.
Vitality Biopharma has found a way to make cannabinoid-based pharmaceuticals without the usual downside of cannabinoids. Namely, Vitality Biopharma’s version of cannabinoids are non-psychotropic, meaning larger, more effective dosing is possible without the ‘high’. It’s this little detail that takes cannabinoid medicine — already the most compelling frontier in the world of pharma — to the next level. There’s a reason some people think the cannabinoid market could be worth $20 billion by 2020.
The idea was significantly advanced in early November. In eight of the nine states voters were asked about legalization of marijuana (for one reason or another), voters said yes….. four for recreational use, and four for medical use. In eight of those nine states, the measures passed. Marijuana is legal in more than half the United States now, and we’re en route to a decided majority in the foreseeable future.
VBIO didn’t necessarily need a sweeping victory at the ballot box, but each time marijuana wins, it seems to advance the discussion of the power of cannabinoids as medicine.
Investors will be able to learn more about Vitality Biopharma’s work in that arena on Thursday of this week. On that day — 8 AM PST / 11 AM EST — at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Robert Brooke, CEO of Vitality Biopharma, will be making a presentation as well as meeting with current and prospective investors.
LD Micro was founded in 2006 with the sole purpose of being an independent resource in t
- [By Matthew Briar]
Back in September, Vitality Biopharma Inc (OTCMKTS:VBIO) CEO Robert Brooke officially announced his company would be entering the painkiller market, specifically taking aim at the development of an alternative to opioids. His specific words? “Opiates are one of the key classes of drugs we’re seeking to replace, or to make far less necessary, as our proprietary cannabosides could provide a potent alternative form of pain relief and help avoid, or greatly reduce, the use of opiates for the treatment of many conditions…”
- [By Jim Robertson]
That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:
- [By Phil Saunders]
Vitality Biopharma, Inc. (OTCBB: VBIO) recent ascent as a strong small cap player in Cannabis pharma, is part of a boom in Cannabis-based pharmaceuticals making announcements about unique and innovative delivery systems being tested for such ailments as Epilepsy, Multiple Sclerosis, and Crohns disease. But it is important to understand how the industry is evolving in the United States and Canada and what that might mean when realizing valuation and the evolution of government policies which still vary from jurisdiction to jurisdiction, making access to Cannabis and the pricing model still a big question moving forward.
Top 5 Medical Stocks To Invest In 2018: Insperity, Inc.(NSP)
- [By Lee Jackson]
Insperity Inc. (NYSE: NSP) also had a large-scale seller on the desk, and it was another well-known hedge fund. Value Act, which also serves as a director at the company, sold a total of 226,000 shares of the stock at prices that ranged from $71.22 to $72.41. The total for the sale was set at $16 million.Insperity provides an array of human resources and business solutions to enhance business performance for small and medium-sized businesses in the United States. The shares closed the day on Friday at $71.85.
Top 5 Medical Stocks To Invest In 2018: Emerald Health Therapeutics, Inc. (TBQBF)
- [By Javier Hasse]
Emerald Health Therapeutics Inc (OTC: TBQBF) raised C$13.8 million ($10.5 million) under a bought deal financing.
“The money will be primarily used for facility expansion."
The Green Solution received a $7.5 million loan facility from iAnthus Capital Holdings Inc (OTC: ITHUF).
Top 5 Medical Stocks To Invest In 2018: ADMA Biologics Inc(ADMA)
- [By Monica Gerson]
The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20: